| scholarly article | Q13442814 |
| P50 | author | Dario Alessi | Q5222818 |
| Nicolas Dzamko | Q57321778 | ||
| Maria Deak | Q28357878 | ||
| Alan R. Prescott | Q37646420 | ||
| P2093 | author name string | Jie Shen | |
| David G Campbell | |||
| Nicholas A Morrice | |||
| Thomas Macartney | |||
| Youren Tong | |||
| Alban Ordureau | |||
| R Jeremy Nichols | |||
| P2860 | cites work | Transfection of mammalian cells using linear polyethylenimine is a simple and effective means of producing recombinant adeno-associated virus vectors | Q40236702 |
| LRRK2 exon 41 mutations in sporadic Parkinson disease in Europeans | Q42165517 | ||
| Dephosphorylation of the inhibitory phosphorylation site S287 in Xenopus Cdc25C by protein phosphatase-2A is inhibited by 14-3-3 binding | Q44151283 | ||
| 14-3-3 protein is a component of Lewy bodies in Parkinson's disease-mutation analysis and association studies of 14-3-3 eta. | Q44247686 | ||
| Phosphorylation-dependent interactions between enzymes of plant metabolism and 14-3-3 proteins | Q77790311 | ||
| Comprehensive analysis of LRRK2 in publicly available Parkinson's disease cases and neurologically normal controls | Q80535570 | ||
| Parkinson's disease-associated mutations in leucine-rich repeat kinase 2 augment kinase activity | Q22254785 | ||
| Leucine-rich repeat kinase 2 (LRRK2) interacts with parkin, and mutant LRRK2 induces neuronal degeneration | Q24298689 | ||
| The Parkinson's disease kinase LRRK2 autophosphorylates its GTPase domain at multiple sites | Q24313336 | ||
| Differential 14-3-3 affinity capture reveals new downstream targets of phosphatidylinositol 3-kinase signaling | Q24319111 | ||
| LRRK2 regulates autophagic activity and localizes to specific membrane microdomains in a novel human genomic reporter cellular model | Q24656256 | ||
| 14-3-3eta is a novel regulator of parkin ubiquitin ligase | Q28115387 | ||
| Mutations in LRRK2 cause autosomal-dominant parkinsonism with pleomorphic pathology | Q28131833 | ||
| alpha-Synuclein shares physical and functional homology with 14-3-3 proteins | Q28139698 | ||
| LRRK2 in Parkinson's disease: protein domains and functional insights | Q28235024 | ||
| Phospho-specific binding of 14-3-3 proteins to phosphatidylinositol 4-kinase III beta protects from dephosphorylation and stabilizes lipid kinase activity | Q28258031 | ||
| Regulation of the polarity kinases PAR-1/MARK by 14-3-3 interaction and phosphorylation | Q28263242 | ||
| Cloning of the gene containing mutations that cause PARK8-linked Parkinson's disease | Q28292932 | ||
| The Structural Basis for 14-3-3:Phosphopeptide Binding Specificity | Q29547190 | ||
| MaxQuant enables high peptide identification rates, individualized p.p.b.-range mass accuracies and proteome-wide protein quantification | Q29547200 | ||
| Phenotype, genotype, and worldwide genetic penetrance of LRRK2-associated Parkinson's disease: a case-control study | Q29614953 | ||
| LRRK2 phosphorylates moesin at threonine-558: characterization of how Parkinson's disease mutants affect kinase activity | Q29615144 | ||
| Kinase activity is required for the toxic effects of mutant LRRK2/dardarin | Q29620478 | ||
| R1441C mutation in LRRK2 impairs dopaminergic neurotransmission in mice. | Q30483115 | ||
| 14-3-3 proteins in the nervous system | Q33188355 | ||
| Interaction of Akt-phosphorylated ataxin-1 with 14-3-3 mediates neurodegeneration in spinocerebellar ataxia type 1. | Q33292483 | ||
| The chaperone activity of heat shock protein 90 is critical for maintaining the stability of leucine-rich repeat kinase 2. | Q33292556 | ||
| Reevaluation of phosphorylation sites in the Parkinson disease-associated leucine-rich repeat kinase 2 | Q34121655 | ||
| Dynamic interactions between 14-3-3 proteins and phosphoproteins regulate diverse cellular processes. | Q35787179 | ||
| Substrate specificity and inhibitors of LRRK2, a protein kinase mutated in Parkinson's disease | Q37139305 | ||
| Zeroing in on LRRK2-linked pathogenic mechanisms in Parkinson's disease. | Q37313530 | ||
| LRRK2 in Parkinson's disease: biochemical functions | Q37608633 | ||
| Differential neuroprotective effects of 14-3-3 proteins in models of Parkinson's disease. | Q39620800 | ||
| P275 | copyright license | Creative Commons Attribution-NonCommercial 2.5 Generic | Q19113746 |
| P6216 | copyright status | copyrighted | Q50423863 |
| P433 | issue | 3 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | cell biology | Q7141 |
| Parkinson's disease | Q11085 | ||
| P304 | page(s) | 393-404 | |
| P577 | publication date | 2010-09-15 | |
| P1433 | published in | Biochemical Journal | Q864221 |
| P1476 | title | 14-3-3 binding to LRRK2 is disrupted by multiple Parkinson's disease-associated mutations and regulates cytoplasmic localization | |
| P478 | volume | 430 |
| Q96304526 | "LRRK2: Autophagy and Lysosomal Activity" |
| Q64863796 | 14-3-3 Proteins Reduce Cell-to-Cell Transfer and Propagation of Pathogenic α-Synuclein |
| Q36402571 | 14-3-3 Proteins regulate mutant LRRK2 kinase activity and neurite shortening. |
| Q36126310 | 14-3-3 inhibition promotes dopaminergic neuron loss and 14-3-3θ overexpression promotes recovery in the MPTP mouse model of Parkinson's disease |
| Q39663092 | 14-3-3 proteins are promising LRRK2 interactors |
| Q35510924 | 14-3-3 proteins as potential therapeutic targets |
| Q28248108 | 14-3-3 proteins in neurodegeneration |
| Q38024792 | 14-3-3 proteins in neurological disorders. |
| Q28742388 | 14-3-3theta Protects against Neurotoxicity in a Cellular Parkinson's Disease Model through Inhibition of the Apoptotic Factor Bax |
| Q132050125 | 14‐3‐3 Protein‐Protein Interactions: From Mechanistic Understanding to Their Small‐Molecule Stabilization |
| Q24310126 | A direct interaction between leucine-rich repeat kinase 2 and specific β-tubulin isoforms regulates tubulin acetylation |
| Q57294610 | A thermodynamic model for multivalency in 14-3-3 protein-protein interactions |
| Q35767234 | A53T-alpha-synuclein-overexpression in the mouse nigrostriatal pathway leads to early increase of 14-3-3 epsilon and late increase of GFAP |
| Q26746897 | Activation Mechanism of LRRK2 and Its Cellular Functions in Parkinson's Disease |
| Q36188579 | Activation of FADD-Dependent Neuronal Death Pathways as a Predictor of Pathogenicity for LRRK2 Mutations |
| Q89611946 | Advances in elucidating the function of leucine-rich repeat protein kinase-2 in normal cells and Parkinson's disease |
| Q47620111 | Age-Dependent Dopaminergic Neurodegeneration and Impairment of the Autophagy-Lysosomal Pathway in LRRK-Deficient Mice |
| Q40501900 | Age-Related Changes of 14-3-3 Isoforms in Midbrain of A53T-SNCA Overexpressing Mice |
| Q37080018 | Altered Development of Synapse Structure and Function in Striatum Caused by Parkinson's Disease-Linked LRRK2-G2019S Mutation |
| Q34282208 | Amygdala 14-3-3ζ as a novel modulator of escalating alcohol intake in mice. |
| Q89484985 | An Assessment of LRRK2 Serine 935 Phosphorylation in Human Peripheral Blood Mononuclear Cells in Idiopathic Parkinson's Disease and G2019S LRRK2 Cohorts |
| Q34300438 | An emerging role for LRRK2 in the immune system |
| Q40106906 | Animal models of α-synucleinopathy for Parkinson disease drug development |
| Q33985278 | Arsenite stress down-regulates phosphorylation and 14-3-3 binding of leucine-rich repeat kinase 2 (LRRK2), promoting self-association and cellular redistribution |
| Q47228597 | Back to the future: new target-validated Rab antibodies for evaluating LRRK2 signalling in cell biology and Parkinson's disease |
| Q92131837 | Binding of the Human 14-3-3 Isoforms to Distinct Sites in the Leucine-Rich Repeat Kinase 2 |
| Q24298093 | Biochemical characterization of highly purified leucine-rich repeat kinases 1 and 2 demonstrates formation of homodimers |
| Q64777632 | Caught in the act: LRRK2 in exosomes |
| Q38433725 | Cellular processes associated with LRRK2 function and dysfunction |
| Q90131498 | Centrosomal cohesion deficits as cellular biomarker in lymphoblastoid cell lines from LRRK2 Parkinson's disease patients |
| Q35780973 | Characterization of a selective inhibitor of the Parkinson's disease kinase LRRK2. |
| Q92815447 | Comparative Genomic Mapping Implicates LRRK2 for Intellectual Disability and Autism at 12q12, and HDHD1, as Well as PNPLA4, for X-Linked Intellectual Disability at Xp22.31 |
| Q26827527 | Current Understanding Of LRRK2 In Parkinson’s Disease: Biochemical And Structural Features And Inhibitor Design |
| Q54980038 | Detection of endogenous S1292 LRRK2 autophosphorylation in mouse tissue as a readout for kinase activity. |
| Q41812724 | Development of an enzyme-linked immunosorbent assay for detection of cellular and in vivo LRRK2 S935 phosphorylation |
| Q37249125 | Development of inducible leucine-rich repeat kinase 2 (LRRK2) cell lines for therapeutics development in Parkinson's disease. |
| Q46253834 | Development of phospho-specific Rab protein antibodies to monitor in vivo activity of the LRRK2 Parkinson's disease kinase |
| Q57022782 | Differences in Stability, Activity and Mutation Effects Between Human and Mouse Leucine-Rich Repeat Kinase 2 |
| Q24299578 | Differential protein-protein interactions of LRRK1 and LRRK2 indicate roles in distinct cellular signaling pathways |
| Q38684995 | Dysregulation of 14-3-3 proteins in neurodegenerative diseases with Lewy body or Alzheimer pathology |
| Q33945342 | Efficient Allele-Specific Targeting of LRRK2 R1441 Mutations Mediated by RNAi |
| Q49322801 | Fbxl18 targets LRRK2 for proteasomal degradation and attenuates cell toxicity |
| Q59125605 | G2019S LRRK2 Increases Stress Susceptibility Through Inhibition of DAF-16 Nuclear Translocation in a 14-3-3 Associated-Manner in Caenorhabditis elegans |
| Q24339009 | G2019S leucine-rich repeat kinase 2 causes uncoupling protein-mediated mitochondrial depolarization |
| Q29347540 | G2385R and I2020T Mutations Increase LRRK2 GTPase Activity |
| Q38814476 | GTP binding regulates cellular localization of Parkinson's disease-associated LRRK2. |
| Q54972398 | Generation of iPSCs carrying a common LRRK2 risk allele for in vitro modeling of idiopathic Parkinson's disease. |
| Q28077356 | Genetics in Parkinson disease: Mendelian versus non-Mendelian inheritance |
| Q27013695 | Heterogeneity of leucine-rich repeat kinase 2 mutations: genetics, mechanisms and therapeutic implications |
| Q38044437 | Human leucine-rich repeat kinase 1 and 2: intersecting or unrelated functions? |
| Q33865491 | Identification of chemicals to inhibit the kinase activity of leucine-rich repeat kinase 2 (LRRK2), a Parkinson’s disease-associated protein |
| Q24317158 | Identification of protein phosphatase 1 as a regulator of the LRRK2 phosphorylation cycle |
| Q40188432 | In silico, in vitro and cellular analysis with a kinome-wide inhibitor panel correlates cellular LRRK2 dephosphorylation to inhibitor activity on LRRK2. |
| Q35691151 | Increased 14-3-3 phosphorylation observed in Parkinson's disease reduces neuroprotective potential of 14-3-3 proteins |
| Q36780383 | Inhibition of LRRK2 kinase activity leads to dephosphorylation of Ser(910)/Ser(935), disruption of 14-3-3 binding and altered cytoplasmic localization |
| Q42372493 | Inhibitor treatment of peripheral mononuclear cells from Parkinson's disease patients further validates LRRK2 dephosphorylation as a pharmacodynamic biomarker |
| Q38234885 | Interaction of LRRK2 with kinase and GTPase signaling cascades |
| Q47414771 | Interrogating Parkinson's disease LRRK2 kinase pathway activity by assessing Rab10 phosphorylation in human neutrophils |
| Q27026262 | Is inhibition of kinase activity the only therapeutic strategy for LRRK2-associated Parkinson's disease? |
| Q34527876 | Kinase drug discovery--what's next in the field? |
| Q35498549 | Kinetic, mechanistic, and structural modeling studies of truncated wild-type leucine-rich repeat kinase 2 and the G2019S mutant |
| Q55410950 | LRRK 2 gene mutations in the pathophysiology of the ROCO domain and therapeutic targets for Parkinson's disease: a review. |
| Q36581417 | LRRK2 BAC transgenic rats develop progressive, L-DOPA-responsive motor impairment, and deficits in dopamine circuit function |
| Q92173150 | LRRK2 Biology from structure to dysfunction: research progresses, but the themes remain the same |
| Q38620229 | LRRK2 Kinase Inhibition as a Therapeutic Strategy for Parkinson's Disease, Where Do We Stand? |
| Q38501861 | LRRK2 Pathways Leading to Neurodegeneration |
| Q51082156 | LRRK2 Phosphorylation |
| Q96953324 | LRRK2 Phosphorylation, More Than an Epiphenomenon |
| Q40899192 | LRRK2 Promotes Tau Accumulation, Aggregation and Release. |
| Q51082145 | LRRK2 and the "LRRKtosome" at the Crossroads of Programmed Cell Death: Clues from RIP Kinase Relatives |
| Q39206438 | LRRK2 and the Immune System |
| Q36185165 | LRRK2 and ubiquitination: implications for kinase inhibitor therapy |
| Q97066874 | LRRK2 and α-Synuclein: Distinct or Synergistic Players in Parkinson's Disease? |
| Q41785779 | LRRK2 dephosphorylation increases its ubiquitination |
| Q48422418 | LRRK2 expression is enriched in the striosomal compartment of mouse striatum |
| Q39137339 | LRRK2 in peripheral and central nervous system innate immunity: its link to Parkinson's disease. |
| Q28078899 | LRRK2 inhibitors and their potential in the treatment of Parkinson's disease: current perspectives |
| Q49651549 | LRRK2 interacts with ATM and regulates Mdm2-p53 cell proliferation axis in response to genotoxic stress |
| Q24300605 | LRRK2 kinase activity and biology are not uniformly predicted by its autophosphorylation and cellular phosphorylation site status |
| Q33999270 | LRRK2 kinase activity is dependent on LRRK2 GTP binding capacity but independent of LRRK2 GTP binding |
| Q24298891 | LRRK2 kinase activity regulates synaptic vesicle trafficking and neurotransmitter release through modulation of LRRK2 macro-molecular complex |
| Q48693369 | LRRK2 knockdown in zebrafish causes developmental defects, neuronal loss, and synuclein aggregation |
| Q39136594 | LRRK2 levels and phosphorylation in Parkinson's disease brain and cases with restricted Lewy bodies. |
| Q28602836 | LRRK2 phosphorylation level correlates with abnormal motor behaviour in an experimental model of levodopa-induced dyskinesias |
| Q42149865 | LRRK2 secretion in exosomes is regulated by 14-3-3. |
| Q38218398 | LRRK2, a puzzling protein: insights into Parkinson's disease pathogenesis |
| Q37635000 | LRRK2: Cause, Risk, and Mechanism |
| Q35170220 | Lack of correlation between the kinase activity of LRRK2 harboring kinase-modifying mutations and its phosphorylation at Ser910, 935, and Ser955. |
| Q48264748 | Lack of exacerbation of neurodegeneration in a double transgenic mouse model of mutant LRRK2 and tau. |
| Q90638116 | Leucine Rich Repeat Kinase 2 and Innate Immunity |
| Q54999237 | Leucine Rich Repeat Kinase 2: beyond Parkinson's and beyond kinase inhibitors. |
| Q37955275 | Leucine-rich repeat kinase 2 (LRRK2) cellular biology: a review of recent advances in identifying physiological substrates and cellular functions |
| Q37829776 | Leucine-rich repeat kinase 2 and alpha-synuclein: intersecting pathways in the pathogenesis of Parkinson's disease? |
| Q34259058 | Leucine-rich repeat kinase 2 for beginners: six key questions. |
| Q38057769 | Leucine-rich repeat kinase 2 inhibitors: a patent review (2006 – 2011) |
| Q39002226 | Leucine-rich repeat kinase 2 inhibitors: a patent review (2014-2016). |
| Q28267434 | Leucine-rich repeat kinase 2 interacts with p21-activated kinase 6 to control neurite complexity in mammalian brain |
| Q35236882 | Leucine-rich repeat kinase 2 modulates neuroinflammation and neurotoxicity in models of human immunodeficiency virus 1-associated neurocognitive disorders |
| Q48239635 | Mechanisms of Mutant LRRK2 Neurodegeneration |
| Q33920691 | Membrane recruitment of endogenous LRRK2 precedes its potent regulation of autophagy |
| Q37582415 | Metabolic labeling of leucine rich repeat kinases 1 and 2 with radioactive phosphate |
| Q47643867 | Mitochondrial Calcium Dysregulation Contributes to Dendrite Degeneration Mediated by PD/LBD-Associated LRRK2 Mutants |
| Q100559468 | Mitochondrial DNA damage as a potential biomarker of LRRK2 kinase activity in LRRK2 Parkinson's disease |
| Q34986076 | Models for LRRK2-Linked Parkinsonism |
| Q58114516 | Models of Sporadic Parkinson's Disease |
| Q51082151 | Molecular Insights and Functional Implication of LRRK2 Dimerization |
| Q40733668 | Multiple regulatory mechanisms for the Dictyostelium Roco protein GbpC. |
| Q24628425 | Mutant LRRK2 elicits calcium imbalance and depletion of dendritic mitochondria in neurons |
| Q54978235 | Mutant LRRK2 mediates peripheral and central immune responses leading to neurodegeneration in vivo. |
| Q24318474 | Mutant LRRK2 toxicity in neurons depends on LRRK2 levels and synuclein but not kinase activity or inclusion bodies |
| Q38173380 | Neuroprotective function of 14-3-3 proteins in neurodegeneration |
| Q59797902 | Nigrostriatal pathology with reduced astrocytes in LRRK2 S910/S935 phosphorylation deficient knockin mice |
| Q37856642 | On the road to leucine-rich repeat kinase 2 signalling: evidence from cellular and in vivo studies |
| Q47222316 | PAK6 Phosphorylates 14-3-3γ to Regulate Steady State Phosphorylation of LRRK2. |
| Q48192270 | Parkinson disease-associated mutations in LRRK2 cause centrosomal defects via Rab8a phosphorylation |
| Q27687171 | Parkinson's disease and immune system: is the culprit LRRKing in the periphery? |
| Q64069540 | Parkinson's disease-associated LRRK2-G2019S mutant acts through regulation of SERCA activity to control ER stress in astrocytes |
| Q24314472 | Parkinson-related LRRK2 mutation R1441C/G/H impairs PKA phosphorylation of LRRK2 and disrupts its interaction with 14-3-3 |
| Q99716681 | Pathogenic LRRK2 requires secondary factors to induce cellular toxicity |
| Q99238235 | Pharmacodynamic Biomarkers for Emerging LRRK2 Therapeutics |
| Q41163700 | Pharmacological LRRK2 kinase inhibition induces LRRK2 protein destabilization and proteasomal degradation |
| Q38044449 | Pharmacological inhibition of LRRK2 cellular phosphorylation sites provides insight into LRRK2 biology. |
| Q37214698 | Phos-tag analysis of Rab10 phosphorylation by LRRK2: a powerful assay for assessing kinase function and inhibitors |
| Q21131229 | Phosphatases of α-synuclein, LRRK2, and tau: important players in the phosphorylation-dependent pathology of Parkinsonism |
| Q28119192 | Phosphoproteomics reveals that Parkinson's disease kinase LRRK2 regulates a subset of Rab GTPases |
| Q24309417 | Phosphorylation of LRRK2 by casein kinase 1α regulates trans-Golgi clustering via differential interaction with ARHGEF7 |
| Q39457004 | Phosphorylation of LRRK2 serines 955 and 973 is disrupted by Parkinson’s disease mutations and LRRK2 pharmacological inhibition |
| Q38044439 | Phosphorylation of LRRK2: from kinase to substrate |
| Q28586694 | Phosphorylation-dependent 14-3-3 binding to LRRK2 is impaired by common mutations of familial Parkinson's disease |
| Q59099056 | Physiological and pathological functions of LRRK2: implications from substrate proteins |
| Q38182492 | Prediction of the repeat domain structures and impact of parkinsonism-associated variations on structure and function of all functional domains of leucine-rich repeat kinase 2 (LRRK2). |
| Q24301070 | Progressive degeneration of human neural stem cells caused by pathogenic LRRK2 |
| Q29347547 | Protective LRRK2 R1398H Variant Enhances GTPase and Wnt Signaling Activity. |
| Q37918059 | Proteostasis and Movement Disorders: Parkinson's Disease and Amyotrophic Lateral Sclerosis |
| Q96304534 | Quantitative Measurements of LRRK2 in Human Cerebrospinal Fluid Demonstrates Increased Levels in G2019S Patients |
| Q47150726 | Rab29 activation of the Parkinson's disease-associated LRRK2 kinase |
| Q24298459 | Rac1 Protein Rescues Neurite Retraction Caused by G2019S Leucine-rich Repeat Kinase 2 (LRRK2) |
| Q34189660 | Recent advances in the genetics of Parkinson's disease |
| Q51082148 | Regulation of LRRK2 by Phosphatases |
| Q60921580 | Roco Proteins: GTPases with a Baroque Structure and Mechanism |
| Q34192817 | Role of LRRK2 kinase dysfunction in Parkinson disease |
| Q35623025 | SPAK/OSR1 regulate NKCC1 and WNK activity: analysis of WNK isoform interactions and activation by T-loop trans-autophosphorylation |
| Q28482925 | Screening for novel LRRK2 inhibitors using a high-throughput TR-FRET cellular assay for LRRK2 Ser935 phosphorylation |
| Q34428227 | Sequences Located within the N-Terminus of the PD-Linked LRRK2 Lead to Increased Aggregation and Attenuation of 6-Hydroxydopamine-Induced Cell Death |
| Q45143202 | Structural and functional in silico analysis of LRRK2 missense substitutions |
| Q38213378 | Structural biology of the LRRK2 GTPase and kinase domains: implications for regulation |
| Q41978493 | Synaptic function is modulated by LRRK2 and glutamate release is increased in cortical neurons of G2019S LRRK2 knock-in mice. |
| Q48132251 | Synthesis and In Vitro and In Vivo Evaluation of [3H]LRRK2-IN-1 as a Novel Radioligand for LRRK2. |
| Q47142767 | Systematic proteomic analysis of LRRK2-mediated Rab GTPase phosphorylation establishes a connection to ciliogenesis. |
| Q39263032 | Targeting LRRK2 in Parkinson's disease: an update on recent developments |
| Q38160939 | Targeting leucine-rich repeat kinase 2 in Parkinson's disease |
| Q41374126 | The G2019S LRRK2 mutation increases myeloid cell chemotactic responses and enhances LRRK2 binding to actin-regulatory proteins. |
| Q51093225 | The G2385R risk factor for Parkinson's disease enhances CHIP-dependent intracellular degradation of LRRK2. |
| Q24324345 | The G2385R variant of leucine-rich repeat kinase 2 associated with Parkinson's disease is a partial loss-of-function mutation |
| Q38044433 | The GTPase function of LRRK2 |
| Q28480459 | The IkappaB kinase family phosphorylates the Parkinson's disease kinase LRRK2 at Ser935 and Ser910 during Toll-like receptor signaling |
| Q33905778 | The LRRK2 G2385R variant is a partial loss-of-function mutation that affects synaptic vesicle trafficking through altered protein interactions. |
| Q52355227 | The LRRK2 Variant E193K Prevents Mitochondrial Fission Upon MPP+ Treatment by Altering LRRK2 Binding to DRP1. |
| Q47225650 | The LRRK2 signalling system |
| Q38111307 | The Neurobiology of LRRK2 and its Role in the Pathogenesis of Parkinson’s Disease |
| Q24293505 | The Parkinson disease-linked LRRK2 protein mutation I2020T stabilizes an active state conformation leading to increased kinase activity |
| Q46428440 | The Upshot of LRRK2 Inhibition to Parkinson's Disease Paradigm |
| Q26778641 | The associations between Parkinson's disease and cancer: the plot thickens |
| Q24298721 | The chaperone-like protein 14-3-3η interacts with human α-synuclein aggregation intermediates rerouting the amyloidogenic pathway and reducing α-synuclein cellular toxicity |
| Q26853537 | The complex relationships between microglia, alpha-synuclein, and LRRK2 in Parkinson's disease |
| Q37513500 | The function of orthologues of the human Parkinson's disease gene LRRK2 across species: implications for disease modelling in preclinical research |
| Q91606425 | The mitochondrial metabolic function of DJ-1 is modulated by 14-3-3β |
| Q36325701 | The role of leucine-rich repeat kinase 2 (LRRK2) in Parkinson's disease |
| Q64811522 | The role of posttranslational modifications of α-synuclein and LRRK2 in Parkinson's disease: Potential contributions of environmental factors |
| Q64859135 | The unlikely partnership between LRRK2 and α-synuclein in Parkinson's disease |
| Q24336432 | Unbiased screen for interactors of leucine-rich repeat kinase 2 supports a common pathway for sporadic and familial Parkinson disease |
| Q35932488 | α-synuclein, LRRK2 and their interplay in Parkinson's disease. |
Search more.